Search the MBS

FDG PET study of the brain, performed for the evaluation of refractory epilepsy which is being evaluated for surgery (R)

Bulk bill incentive

Fee: $918.00 Benefit: 75% = $688.50 85% = $819.30

(See para IN.0.19 of explanatory notes to this Category)

• Previous - Item 61553
• Next - Item 61560

FDG PET study of the brain, performed for the diagnosis of Alzheimer’s disease, if:

1. clinical evaluation of the patient by a specialist, or in consultation with a specialist, is equivocal; and
2. the service includes a quantitative comparison of the results of the study with the results of an FDG PET study of a normal brain from a reference database; and
3. a service to which this item applies has not been performed on the patient in the previous 12 months; and
4. a service to which item 61402 applies has not been performed on the patient in the previous 12 months for the diagnosis or management of Alzheimer’s disease

Applicable not more than 3 times per lifetime (R)

Bulk bill incentive

Fee: $605.05 Benefit: 75% = $453.80 85% = $514.30

• Previous - Item 61559
• Next - Item 61563

Whole body prostate-specific membrane antigen PET study performed for
the initial staging of intermediate to high-risk prostate adenocarcinoma, for a
previously untreated patient who is considered suitable for locoregional
therapy with curative intent

Applicable once per lifetime (R)

Bulk bill incentive

Fee: $1,300.00 Benefit: 75% = $975.00 85% = $1,201.30

(See para IN.0.17, IN.0.19 of explanatory notes to this Category)

• Previous - Item 61560
• Next - Item 61564

Whole body prostate-specific membrane antigen PET study performed for
the restaging of recurrent prostate adenocarcinoma, for a patient who:
(a) has undergone prior locoregional therapy; and
(b) is considered suitable for further locoregional therapy to determine
appropriate therapeutic pathways and timing of treatment initiation

Applicable twice per lifetime (R)

Bulk bill incentive

Fee: $1,300.00 Benefit: 75% = $975.00 85% = $1,201.30

(See para IN.0.17, IN.0.19 of explanatory notes to this Category)

• Previous - Item 61563
• Next - Item 61565

Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy. (R)

Bulk bill incentive

Fee: $953.00 Benefit: 75% = $714.75 85% = $854.30

(See para IN.0.19 of explanatory notes to this Category)

• Previous - Item 61564
• Next - Item 61571

Whole body FDG PET study, for the further primary staging of  patients with histologically proven carcinoma of the uterine cervix, at FIGO stage IB2 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent. (R)

Bulk bill incentive

Fee: $953.00 Benefit: 75% = $714.75 85% = $854.30

• Previous - Item 61565
• Next - Item 61575

Whole body FDG PET study, for the further staging of patients with confirmed local recurrence of carcinoma of the uterine cervix considered suitable for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent. (R)

Bulk bill incentive

Fee: $953.00 Benefit: 75% = $714.75 85% = $854.30

• Previous - Item 61571
• Next - Item 61577

Whole body FDG PET study, performed for the staging of proven oesophageal or GEJ carcinoma, in patients considered suitable for active therapy (R).

Bulk bill incentive

Fee: $953.00 Benefit: 75% = $714.75 85% = $854.30

• Previous - Item 61575
• Next - Item 61598

Whole body FDG PET study performed for the staging of biopsy-proven newly diagnosed or recurrent head and neck cancer (R).

Bulk bill incentive

Fee: $953.00 Benefit: 75% = $714.75 85% = $854.30

• Previous - Item 61577
• Next - Item 61604

Whole body FDG PET study performed for the evaluation of patients with suspected residual head and neck cancer after definitive treatment, and who are suitable for active therapy (R).

Bulk bill incentive

Fee: $953.00 Benefit: 75% = $714.75 85% = $854.30

• Previous - Item 61598
• Next - Item 61610